Clinical trial results:
An Extension Study to Evaluate Long Term Safety of Subcutaneous Tocilizumab in Subjects with Giant Cell Arteritis Who Have Completed WA28119 Core Study in France, and Subsequently having Flare or Persisting Disease Activity.

Summary

EudraCT number	2016-002716-41
Trial protocol	FR
Global end of trial date	23 August 2019

Results information

Result version number	v1 (current)
This version publication date	05 September 2020
First version publication date	05 September 2020

Trial information

Trial identification

Sponsor protocol code	ML39425

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03202368
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	F. Hoffmann-La Roche AG
Sponsor organisation address	Grenzacherstrasse 124, Basel, Switzerland, CH-4070
Public contact	F. Hoffmann-La Roche AG, Roche Trial Information Hotline, +41 61 6878333, global.trial_information@roche.com
Scientific contact	F. Hoffmann-La Roche AG, Roche Trial Information Hotline, +41 61 6878333, global.trial_information@roche.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	01 July 2020
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	23 August 2019
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

This is a multicenter, interventional, open-label, long-term extension study of Study WA28119 (NCT01791153) to evaluate the long-term safety of SC tocilizumab in subjects with GCA who subsequently have flare or persisting disease activity.

Protection of trial subjects:

All study subjects were required to read and sign and Informed Consent Form. The study was conducted in accordance with the principles of the "Declaration of Helsinki" and Good Clinical Practice.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	25 October 2017
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	France: 3
Worldwide total number of subjects	3
EEA total number of subjects	3

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	3
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Subjects who were treated with tocilizumab in Study WA28119 and experienced a new GCA flare within 3 years after completion of Study WA28119 or had persistent active GCA at the time of completion of Study WA28119, will receive SC tocilizumab in this study.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	Tocilizumab: GCA Flare or Persistent Disease Activity

Arm description:

Subjects who were treated with tocilizumab in Study WA28119 and experienced a new GCA flare within 3 years after completion of Study WA28119 or had persistent active GCA at the time of completion of Study WA28119.

Arm type	Experimental
Investigational medicinal product name	Tocilizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

162 milligrams (mg) of tocilizumab every week for a maximum of 156 weeks or until the commercial availability of tocilizumab, whichever comes first.

Number of subjects in period 1	Tocilizumab: GCA Flare or Persistent Disease Activity
Started	3
Completed	2
Not completed	1
Adverse event, non-fatal	1

Baseline characteristics

Reporting groups	
Reporting group title	Overall Study
Reporting group description:	
Subjects who were treated with tocilizumab in Study WA28119 and experienced a new GCA flare within 3 years after completion of Study WA28119 or had persistent active GCA at the time of completion of Study WA28119.	

Reporting group values	Overall Study	Total	
Number of subjects	3	3	
Age Categorical Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	0	0	
From 65-84 years	3	3	
85 years and over	0	0	
Age Continuous Units: years			
arithmetic mean	74.7		
standard deviation	± 3.8	-	
Gender Categorical Units: Subjects			
Female	3	3	
Male	0	0	

End points

End points reporting groups

Reporting group title	Tocilizumab: GCA Flare or Persistent Disease Activity

Reporting group description:

Subjects who were treated with tocilizumab in Study WA28119 and experienced a new GCA flare within 3 years after completion of Study WA28119 or had persistent active GCA at the time of completion of Study WA28119.

Primary: Percentage of subjects with Adverse Events

End point title	Percentage of subjects with Adverse Events[1]

End point description:

Due to the limited number of analyzed subjects (n=3), only descriptive analysis at each study visit was performed, with no change from baseline

End point type	Primary

End point timeframe:

Baseline up to 160 weeks

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analysis provided.

End point values	Tocilizumab: GCA Flare or Persistent Disease Activity			
Subject group type	Reporting group			
Number of subjects analysed	3			
Units: Percentage				
number (not applicable)				
Adverse Events	100			
Serious Adverse Events	33.3			

Statistical analyses

No statistical analyses for this end point

Secondary: GCA Disease Activity, as Assessed by the Investigator Based on Visual Analogue Scale Score

End point title	GCA Disease Activity, as Assessed by the Investigator Based on Visual Analogue Scale Score

End point description:

Due to the limited number of analyzed subjects (n=3), only descriptive analysis at each study visit was performed, with no change from baseline.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Weeks 48, 96, 156

End point values	Tocilizumab: GCA Flare or Persistent Disease Activity			
Subject group type	Reporting group			
Number of subjects analysed	0[2]			
Units: Points on Scale				

Notes:

[2] - Only descriptive analysis at each study visit was performed.

Statistical analyses

No statistical analyses for this end point

Secondary: Patient Global Assessment of Disease Activity Disease Activity, as Assessed Based on Visual Analogue Scale Score

End point title	Patient Global Assessment of Disease Activity Disease Activity, as Assessed Based on Visual Analogue Scale Score

End point description:

Due to the limited number of analyzed subjects (n=3), only descriptive analysis at each study visit was performed, with no change from baseline.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Weeks 48, 96, 156

End point values	Tocilizumab: GCA Flare or Persistent Disease Activity			
Subject group type	Reporting group			
Number of subjects analysed	0[3]			
Units: Points on Scale				

Notes:

[3] - Only descriptive analysis at each study visit was performed.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Erythrocyte Sedimentation Rate Values

End point title	Change from Baseline in Erythrocyte Sedimentation Rate Values

End point description:

Due to the limited number of analyzed subjects (n=3), only descriptive analysis at each study visit was performed, with no change from baseline.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Weeks 48, 96, 156

End point values	Tocilizumab: GCA Flare or Persistent Disease Activity			
Subject group type	Reporting group			
Number of subjects analysed	0[4]			
Units: mm/hr				

Notes:

[4] - Only descriptive analysis at each study visit was performed.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in C-Reactive Protein Values

End point title	Change from Baseline in C-Reactive Protein Values

End point description:

Due to the limited number of analyzed subjects (n=3), only descriptive analysis at each study visit was performed, with no change from baseline.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Weeks 48, 96, 156

End point values	Tocilizumab: GCA Flare or Persistent Disease Activity			
Subject group type	Reporting group			
Number of subjects analysed	0[5]			
Units: mg/L				

Notes:

[5] - Only descriptive analysis at each study visit was performed.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects Who Receive Concomitant Medications With SC Tocilizumab

End point title	Number of Subjects Who Receive Concomitant Medications With SC Tocilizumab

End point description:

Due to the limited number of analyzed subjects (n=3), only descriptive analysis at each study visit was

performed, with no change from baseline.

End point type	Secondary

End point timeframe:

Baseline up to 156 weeks

End point values	Tocilizumab: GCA Flare or Persistent Disease Activity			
Subject group type	Reporting group			
Number of subjects analysed	0[6]			
Units: Number of subjects				

Notes:

[6] - Only descriptive analysis at each study visit was performed.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of SC Tocilizumab Injections Administered

End point title	Number of SC Tocilizumab Injections Administered

End point description:

Due to the limited number of analyzed subjects (n=3), only descriptive analysis at each study visit was performed, with no change from baseline.

End point type	Secondary

End point timeframe:

Baseline up to 156 weeks

End point values	Tocilizumab: GCA Flare or Persistent Disease Activity			
Subject group type	Reporting group			
Number of subjects analysed	0[7]			
Units: Number				

Notes:

[7] - Only descriptive analysis at each study visit was performed.

Statistical analyses

No statistical analyses for this end point

Secondary: Total SC Tocilizumab Dose Administered

End point title	Total SC Tocilizumab Dose Administered

End point description:

Due to the limited number of analyzed subjects (n=3), only descriptive analysis at each study visit was performed, with no change from baseline.

End point type	Secondary

End point timeframe:

Baseline up to 156 weeks

End point values	Tocilizumab: GCA Flare or Persistent Disease Activity			
Subject group type	Reporting group			
Number of subjects analysed	0[8]			
Units: Number				

Notes:

[8] - Only descriptive analysis at each study visit was performed.

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of SC Tocilizumab Treatment

End point title	Duration of SC Tocilizumab Treatment

End point description:

Due to the limited number of analyzed subjects (n=3), only descriptive analysis at each study visit was performed, with no change from baseline.

End point type	Secondary

End point timeframe:

Baseline up to 156 weeks

End point values	Tocilizumab: GCA Flare or Persistent Disease Activity			
Subject group type	Reporting group			
Number of subjects analysed	0[9]			
Units: Weeks				

Notes:

[9] - Only descriptive analysis at each study visit was performed.

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of SC Tocilizumab Interruption

End point title	Duration of SC Tocilizumab Interruption

End point description:

Due to the limited number of analyzed subjects (n=3), only descriptive analysis at each study visit was performed, with no change from baseline.

End point type	Secondary

End point timeframe:

Baseline up to 156 weeks

End point values	Tocilizumab: GCA Flare or Persistent Disease Activity			
Subject group type	Reporting group			
Number of subjects analysed	0[10]			
Units: Weeks				

Notes:

[10] - Only descriptive analysis at each study visit was performed.

Statistical analyses

No statistical analyses for this end point

Secondary: Duration Between Last Tocilizumab Administration in Study WA28119 and First Tocilizumab Administration in Current Study

End point title	Duration Between Last Tocilizumab Administration in Study WA28119 and First Tocilizumab Administration in Current Study

End point description:

Due to the limited number of analyzed subjects (n=3), only descriptive analysis at each study visit was performed, with no change from baseline.

End point type	Secondary

End point timeframe:

From last tocilizumab administration in Study WA28119 to first tocilizumab administration in current study (approximately up to 3 years; assessed retrospectively at Baseline)

End point values	Tocilizumab: GCA Flare or Persistent Disease Activity			
Subject group type	Reporting group			
Number of subjects analysed	0[11]			
Units: Weeks				

Notes:

[11] - Only descriptive analysis at each study visit was performed.

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information	
Timeframe for reporting adverse events: Baseline up to 160 weeks	
Assessment type	Systematic
Dictionary used	
Dictionary name	MedDRA
Dictionary version	22.1
Reporting groups	
Reporting group title	Tocilizumab: GCA Flare or Persistent Disease Activity
Reporting group description: Subjects who were treated with tocilizumab in Study WA28119 and experienced a new GCA flare within 3 years after completion of Study WA28119 or had persistent active GCA at the time of completion of Study WA28119.	

Serious adverse events	Tocilizumab: GCA Flare or Persistent Disease Activity		
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 3 (33.33%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Cardiac disorders			
Trachycardia			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Tocilizumab: GCA Flare or Persistent Disease Activity		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	3 / 3 (100.00%)		
Cardiac disorders			
Tachycardia			
subjects affected / exposed	2 / 3 (66.67%)		
occurrences (all)	3		
Nervous system disorders			

Headache			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Blood and lymphatic system disorders			
Lymphopenia			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Skin and subcutaneous tissue disorders			
Urticarial vasculitis			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Rheumatic disorder			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Infections and infestations			
Bronchitis			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Ear infection			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Erysipelas			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Periodontitis			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Tonsillitis			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Tracheitis			

subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Urinary tract infection			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported